Oculis Holding AG (NASDAQ:OCS – Get Free Report) fell 1.4% during trading on Tuesday . The stock traded as low as $9.70 and last traded at $9.71. 27,856 shares were traded during trading, an increase of 35% from the average session volume of 20,579 shares. The stock had previously closed at $9.85.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on OCS shares. Stifel Nicolaus started coverage on shares of Oculis in a research note on Wednesday, October 4th. They set a “buy” rating and a $35.00 target price for the company. Bank of America upped their price objective on shares of Oculis from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, August 29th. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Oculis in a research note on Wednesday, August 30th. Finally, Robert W. Baird upped their price objective on shares of Oculis from $58.00 to $64.00 in a research note on Wednesday, August 9th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $33.67.
Oculis Trading Down 1.4 %
Oculis (NASDAQ:OCS – Get Free Report) last issued its quarterly earnings results on Tuesday, August 29th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The company had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.28 million. Sell-side analysts forecast that Oculis Holding AG will post -2.91 EPS for the current year.
Hedge Funds Weigh In On Oculis
Several hedge funds and other institutional investors have recently bought and sold shares of OCS. Barclays PLC purchased a new stake in Oculis in the 2nd quarter worth approximately $44,000. Ergoteles LLC purchased a new position in shares of Oculis during the 2nd quarter valued at approximately $247,000. HRT Financial LP purchased a new position in shares of Oculis during the 1st quarter valued at approximately $178,000. Compagnie Lombard Odier SCmA purchased a new position in shares of Oculis during the 1st quarter valued at approximately $472,000. Finally, Nan Fung Group Holdings Ltd acquired a new position in Oculis in the 1st quarter valued at $4,838,000. Institutional investors and hedge funds own 14.28% of the company’s stock.
Oculis Company Profile
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
- Five stocks we like better than Oculis
- Why Are Stock Sectors Important to Successful Investing?
- GSK is a remedy for the winter investment blahs
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- After blowout earnings, Integer may be headed to new highs
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Banking and trucking: Is the economy rolling toward troubles?
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.